Abingdon Health Plc (ABDX) fair value: what the stock is really worth
We calculate from audited financials what Abingdon Health Plc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Jun 24, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch Abingdon Health Plc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 24, 2026.
How to read this chart
60‑month range £0.0375 – £0.6231 · fair‑value band £0.0595 – £0.1020 · the £0.1050 price screens above the £0.0765 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Jun 24, 2026.
Follow Abingdon Health in your weekly email
Every Wednesday you see whether Abingdon Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Abingdon Health Plc develops, manufactures, and distributes diagnostic devices in the United Kingdom, Europe, the United States, Canada, and internationally. It operates through Contract Development, Contract Manufacturing, Product Sales, and Regulatory segments.
Show more
Abingdon Health Plc develops, manufactures, and distributes diagnostic devices in the United Kingdom, Europe, the United States, Canada, and internationally. It operates through Contract Development, Contract Manufacturing, Product Sales, and Regulatory segments. The company provides a range of professional-use tests and self-tests to various industries, including healthcare, COVID-19, plant health, and nucleic acid detection. Abingdon Health Plc was incorporated in 2008 and is based in York, the United Kingdom.
Stock analysis
Abingdon Health Plc (ABDX) currently trades at £0.1050, while our model-based Fair Value estimate is £0.0765, implying the stock looks roughly 37.2% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: £0.0595 (bear) to £0.1020 (bull), the price of £0.1050 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Abingdon Health Plc reported revenue of £8.4M in FY2025 versus £11.6M in FY2021, a compound −7.7%/yr. Reported net income was −£3.4M in FY2025.
Key figures
Market cap 38.5M GBX · P/S ratio 2.49 · EPS (TTM) £−0.0100 · Net margin −40.5% · Return on equity −51.0% · Return on assets (EBIT) −49.0% · Operating margin −53.9% · Revenue (TTM) £9.6M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 18% below its 52-week high and 81% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −27%, ABDX screens richer than that median.
Fair Value models
Bear £0.0595Fair Value £0.0765Bull £0.1020
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.27/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+37.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+43.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.2%
’16
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−61.3% (2019) → −47.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks
Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score33 · Bottom 25%
Fair Value upside−27% · Above median
Profitability
Return on assets−24% · Bottom 25%
Net margin (TTM)−34% · Bottom 25%
Operating margin (TTM)−54% · Bottom 25%
Growth and dividend
Revenue growth37% · Top 25%
Balance sheet
Debt / equity0.12× · Above median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/B9.62× · Priciest 25%
P/S (TTM)5.33× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 25
PAST (return on equity)0· sector 8
HEALTH (low debt)94· sector 95
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Abingdon Health Plc Fair Value". https://www.fairvalue-calculator.com/stock/ABDX
Frequently asked questions
Is Abingdon Health Plc (ABDX) overvalued or undervalued?
As of Jun 24, 2026, our model estimates a fair value of £0.0765 versus a price of £0.1050, about −27% upside (overvalued).
What is the fair value of ABDX?
Our model-based fair value for Abingdon Health Plc is £0.0765 (as of Jun 24, 2026), built from audited fundamentals. The current price: £0.1050.
What is the quality score of ABDX?
Abingdon Health Plc has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Abingdon Health Plc (ABDX)?
Our model-based price target is the fair value of £0.0765 (as of Jun 24, 2026) from 1 valuation models. Cautious scenario £0.0595, optimistic scenario £0.1020. It is a calculation from audited fundamentals, not an analyst target.
What is the Abingdon Health Plc stock forecast for 2026?
Our models put fair value at £0.0765, about −27% upside versus a price of £0.1050 (overvalued). Cautious scenario £0.0595, optimistic scenario £0.1020. The calculation is refreshed regularly with new filings.
What is the revenue of Abingdon Health Plc (ABDX)?
Abingdon Health Plc reported trailing-twelve-month revenue of about £9.6M (latest available figure, as of Jun 24, 2026).
What is the intrinsic value of Abingdon Health Plc (ABDX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Abingdon Health Plc it is £0.0765 per share (as of Jun 24, 2026), against a price of £0.1050. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Abingdon Health Plc stock overvalued or undervalued in 2026?
As of Jun 24, 2026, ABDX trades above its calculated fair value: price £0.1050, fair value £0.0765, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ABDX?
No. The price is what the market pays today (£0.1050); the fair value is what the company's own numbers justify (£0.0765). For Abingdon Health Plc the two are £0.0285 per share apart. That gap is exactly why we show both numbers side by side.
How much is Abingdon Health Plc worth?
The market values Abingdon Health Plc at about 38.5M GBX (market capitalisation, as of Jun 24, 2026). Per share that is £0.1050; our models calculate a fair value of £0.0765 per share.
What do the bullish and bearish scenarios say about ABDX?
Our models span a range for Abingdon Health Plc: cautious scenario £0.0595, base £0.0765, optimistic £0.1020 per share (as of Jun 24, 2026, price £0.1050). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Abingdon Health Plc (ABDX)?
Balance-sheet figures for Abingdon Health Plc (as of Jun 24, 2026): return on equity −51.0%, debt of 0.12 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is ABDX from its 52-week high?
Abingdon Health Plc trades at £0.1050, about 18% below its 52-week high of £0.1275 and 81% above the low of £0.0580 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of £0.0765 is for.
Which stocks are comparable to Abingdon Health Plc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Abingdon Health Plc stock attractive at the current price?
The data as of Jun 24, 2026: price £0.1050, calculated fair value £0.0765 (−27%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ABDX calculated?
We run Abingdon Health Plc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £0.0765, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Abingdon Health Plc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Abingdon Health Plc (ABDX)?
The closing price on Sep 24, 2026 was £0.1050. Our model-based fair value is £0.0765, about −27% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Abingdon Health Plc right now?
The price sits above even our optimistic bull case (£0.1020). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Abingdon Health Plc
How large is the market capitalisation of Abingdon Health Plc (ABDX)?
The market capitalisation of Abingdon Health Plc is 38.5M GBX. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Abingdon Health Plc (ABDX)?
The price-to-sales ratio of Abingdon Health Plc is 2.49 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Abingdon Health Plc (ABDX)?
Earnings per share at Abingdon Health Plc are £−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Abingdon Health Plc (ABDX)?
The net margin of Abingdon Health Plc is −40.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Abingdon Health Plc (ABDX)?
The return on equity (ROE) of Abingdon Health Plc is −51.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Abingdon Health Plc (ABDX)?
On an EBIT basis the return on assets of Abingdon Health Plc is −49.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Abingdon Health Plc (ABDX)?
The operating margin of Abingdon Health Plc is −53.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Abingdon Health Plc (ABDX)?
Revenue at Abingdon Health Plc is growing +36.9% versus a year earlier (3y avg +43.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Abingdon Health Plc (ABDX) generate?
The free cash flow of Abingdon Health Plc is −3.4M GBX (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Abingdon Health Plc (ABDX) hold?
Abingdon Health Plc holds more cash than debt, 890K GBX net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Abingdon Health Plc in the live analysis
One click puts Abingdon Health Plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
